Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcriptClaire Lucas(University of Chester), R E Clark(University of Liverpool)HaematologicaAugust 27, 200910.3324/haematol.2009.009134Cited by 118SaveCiteExport RISWatch citationsRelated PapersHigh CIP2A levels correlate with an antiapoptotic phenotype that can be overcome by targeting BCL-XL in chronic myeloid leukemia|Leukemia|2016|27